Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaSubgroupICD10C82.-C82.7C82.9C83.0C83.1C83.3C88.0-MeSHLymphoma, Mantle-CellSequenceChemotherapyChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabChemo-substanceCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabNo. Substances6 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimNo. Substances6Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseSalvageTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO)Febrile Neutropenia only studiesPublicationAuthorKirschey SDiseaserezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2OriginDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzProtocols in Revision 1 protocol foundProtocols under revision.R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)
